ZiggyLabs completes study which provides evidence of anti-cancer potential drugs for animals

ZiggyLabs are pleased to announce it has just completed a study which aimed to identify the mechanisms of actions of several lead candidate drugs observed to exhibit anti-tumour properties during our high-throughput drug screen.

Although each drug had a unique mechanism of action, reflecting the different molecular structures and direct targets of these drugs, all of the drugs studied were found to result in the increased expression of a protein which interacts with a second protein known to be the main driver of tumour progression.

This not only provides strong evidence that these drugs have anti-cancer potential, but also suggests that this protein may have utility as a direct drug target in this tumour type.

ZiggyLabs

ZiggyLabs, established in late 2016, is a boutique, R&D-focussed animal health company committed to winning the fight against cancer in dogs and cats. Currently, our focus is on developing therapies for hemangiosarcoma (HSA), a devastating, always-fatal blood malignancy with no effective treatment to date. We use a drug repositioning model, investigating existing drugs to identify their efficacy in cancer therapy.

Register Interest